Box 1. The Bethesda Statement on Open-Access Publishing
This is taken from http:⁄⁄www.earlham.edu/~peters/fos/bethesda.htm.
An Open Access Publication 1 is one that meets the following two conditions:
1. The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship 2 , as well as the right to make small numbers of printed copies for their personal use.
2. A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other wellestablished organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving (for the biomedical sciences, PubMed Central is such a repository). 1 Open access is a property of individual works, not necessarily journals or publishers. 2 Community standards, rather than copyright law, will continue to provide the mechanism for enforcement of proper attribution and responsible use of the published work, as they do now.
New York Times science writer Carl
Zimmer demonstrated the distinction succinctly [4] . He discusses a recent case where Wiley threatened legal action after a neuroscience graduate posted some fi gures from one of their journal articles on her blog (despite the fact that this is already permitted under terms of "fair dealing" or "fair use"). No. I hear the blissful silence of Open Access, a slowly-spreading trend in the journal world. PLOS makes it very clear on their web site that "everything we publish is freely available online throughout the world, for you to read, download, copy, distribute, and use (with attribution) any way you wish." No muss, no fuss. If I want to blog about this paper right now, I can grab a relevant image right now from it. In fact, I just did." [4] Subsequent to an outcry within the blogoshpere (for a summary, see [5] ), Wiley withdrew their threat of legal action. But the license that enabled Zimmer to extract the information he needed without worry is used by all the established open-access publishers, such as PLoS, BioMed Central, and Hindawi, as well as some traditional publishers, such as Oxford University Press (OUP). Examples of the license from some journals are given in Box 2, and each statement is explicit about how the article may be used. In all cases, copyright is held by the authors, although this is not strictly necessary; as long as there is unrestricted derivative use, the copyright could be held by the author or the publisher and still be regarded as open access.
Other journals purporting to be "open access" or publishers with an "open-access option" are not all that they seem. Take, for example, the journal Molecular Systems Biology. This is listed as an open-access journal by the DOAJ and published by the Nature Publishing Group. the authors-or, more likely, their funding agencies-agreed to pay for here? It is certainly not open access as defi ned by the Bethesda Statement [2] .
Some journals do not claim to be fully open access but provide an "openaccess option" that permits articles to be deposited in PMC and thus conforms to the minimum guidelines set by, e.g., the Wellcome Trust. But confusion abounds here as well. If you search various journal sites for "open-access" options, you'll fi nd it enormously diffi cult to obtain clearly labeled information describing how you can use the article. Often an article is free to read, and has been deposited in the US PMC, but it's not clear from the terms on the article that it can be distributed freely to others or reused without explicit permission from the appropriate permissions department. Again, this is not open access.
A particularly befuddling example comes from the Journal of Biological Chemistry (JBC). The JBC website states that it is an "open-access" journal and that their publisher-the American Society for Biochemistry and Molecular Biology (ASBMB)-is an "openaccess" publisher (http:⁄⁄www.jbc. org/misc/JBC_Open_Access.shtml). They don't charge a publication fee as such but do have page charges like many traditional journals (US$75 per published page). What you actually fi nd is that manuscripts that are currently in press are available for free but those published in the current issue are not. On the table of contents of the current issue, there is a helpful permissions button next to each article that links to a webpage that helps you calculate the charges for different uses (even for posting on the internet). It is unclear how this qualifi es as open access.
Does the distinction between free and open access really matter if anyone can read the article for free? Isn't open access just about making the literature available? Well, yes and no. Free access is certainly important, but it's only the starting point. At least of equal importance is the potential for innovation. We don't know yet what innovation means with regards to the full text of an article-who could have predicted the impact GenBank would have or the uses that sequences are now being put to? As one colleague put it, free access is like giving a child a Lego car and telling her that she can look at it, perhaps touch it, but certainly not take it apart and make an airplane from it. The full potential of the work cannot be realized [6] .
What's worrying is that there are already examples of publishers restricting use of their "free-access" articles, even in international repositories. For example, some of the publishers that currently allow their articles to be deposited in the US PMC will not allow those same articles to be mirrored and made available from the UK site (a list of these journals can be found at http:⁄⁄ukpmc.ac.uk/ppmclocalhtml/not_in_ukpmc.html). It's hard to understand the reasoning for this limitation-after all, the articles are freely available from the US site. But what's disturbing is that publishers can act like this because the articles themselves are not truly open accesswho knows what further restrictions might be placed on these articles in the future.
So although true open access is unquestionably good for science, there is a real concern that the precise meaning of the term is being corrupted and eroded. Not all of the confusion about open access that currently permeates the scholarly publishing industry is likely to be intentional (at least not all of it); much arises from a genuine misunderstanding of open access by funders, authors, editors, and publishers alike. However, no matter how unintentional such obfuscation might be, it is detrimental to the free exchange and use of scholarly research. It is now time for all publishers to tighten the defi nition and application of open access and be clearer about the uses and restrictions applied to their articles. Open access is a term that should only be used when the license permits both free access and unrestricted derivative use (and gives appropriate attribution). Authors and funders need to be much more aware of the small print before inadvertently signing away their rights and those of their readers and, even worse, paying good money for the privilege.
Perhaps the real key to establishing a broad consensus around the meaning of open access will be the development of resources that demonstrate the potential of unrestricted reuse of the literaturethe "Lego factor." If certain work is not included in these resources because of restrictive license agreements, authors will probably pay much closer attention to the claim that a publisher is "open access." Enlightened self-interest can be a powerful force.
